Question · asked by 1 review

Any systemic treatment vs placebo: Risankizumab

Population
people with chronic plaque psoriasis
Intervention
Any systemic treatment
Comparison
placebo
Outcome
Risankizumab

Any systemic treatment probably leads to lower risankizumab compared with placebo (moderate certainty).

What each review found

Current versions only
No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 1 · 50%High 1 · 50%
FindingEffectStudiesGRADE certainty
Any systemic treatment vs placebo
Risankizumab · people with chronic plaque psoriasis
Any systemic treatment probably leads to lower risankizumab compared with placebo (moderate certainty).
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis (2020) · Cochrane Headline outcomes only
RR 0.6 [0.37, 0.96]4 studies · 1476 participantsModerate
Any systemic treatment vs placebo
Risankizumab · people with chronic plaque psoriasis
Any systemic treatment leads to higher risankizumab compared with placebo (high certainty).
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis (2020) · Cochrane Headline outcomes only
RR 27.67 [22.86, 33.49]4 studies · 1476 participantsHigh

Findings are shown side by side, never pooled across reviews.

The reviews

ReviewSearched up toIncluded studiesAMSTAR 2
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
2020 · Cochrane Headline outcomes only
Not reportedNot extractedNot assessed
How reviews are matched to this question

Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.